These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 3742787

  • 1. Sub-class of IgG anti-bee venom antibody produced during bee venom immunotherapy and its relationship to long-term protection from bee stings and following termination of venom immunotherapy.
    Urbanek R, Kemeny DM, Richards D.
    Clin Allergy; 1986 Jul; 16(4):317-22. PubMed ID: 3742787
    [Abstract] [Full Text] [Related]

  • 2. Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens.
    Kemeny DM, MacKenzie-Mills M, Harries MG, Youlten LJ, Lessof MH.
    J Allergy Clin Immunol; 1983 Oct; 72(4):376-85. PubMed ID: 6619452
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom.
    Müller U, Helbling A, Bischof M.
    Allergy; 1989 Aug; 44(6):412-8. PubMed ID: 2802114
    [Abstract] [Full Text] [Related]

  • 5. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.
    Ewan PW, Deighton J, Wilson AB, Lachmann PJ.
    Clin Exp Allergy; 1993 Aug; 23(8):647-60. PubMed ID: 8221268
    [Abstract] [Full Text] [Related]

  • 6. Antibodies to purified bee venom proteins and peptides. I. Development of a highly specific RAST for bee venom antigens and its application to bee sting allergy.
    Kemeny DM, Harries MG, Youlten LJ, Mackenzie-Mills M, Lessof MH.
    J Allergy Clin Immunol; 1983 May; 71(5):505-14. PubMed ID: 6601672
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discontinuation of bee venom immunotherapy in children and adolescents.
    Urbanek R, Forster J, Kuhn W, Ziupa J.
    J Pediatr; 1985 Sep; 107(3):367-71. PubMed ID: 4032132
    [Abstract] [Full Text] [Related]

  • 9. Changes in the levels of anti-phospholipase A2 and hyaluronidase antibodies during bee venom immunotherapy.
    Kemeny DM, McKenzie-Mills M, Harries MG, Youlten LJ, Lessof MH.
    Monogr Allergy; 1983 Sep; 18():150-2. PubMed ID: 6646134
    [No Abstract] [Full Text] [Related]

  • 10. Neutralization of bee venom lethality by immune serum antibodies.
    Schumacher MJ, Egen NB, Tanner D.
    Am J Trop Med Hyg; 1996 Aug; 55(2):197-201. PubMed ID: 8780460
    [Abstract] [Full Text] [Related]

  • 11. Isotypic and idiotypic characterization of anti-bee venom phospholipase A2 antibodies.
    Wetterwald A, Skvaril F, Müller U, Blaser K.
    Int Arch Allergy Appl Immunol; 1985 Aug; 77(1-2):195-7. PubMed ID: 4008074
    [Abstract] [Full Text] [Related]

  • 12. [The key role of IgG4 subclass antibodies in the development of protection against allergic reactions to insect stings].
    Urbanek R, Dold S.
    Monatsschr Kinderheilkd; 1986 Aug; 134(8):536-40. PubMed ID: 3773921
    [Abstract] [Full Text] [Related]

  • 13. The immune response to bee venom. Comparison of the antibody response to phospholipase A2 with the response to inhalant antigens.
    Kemeny DM, Miyachi S, Platts-Mills TA, Wilkins S, Lessof MH.
    Int Arch Allergy Appl Immunol; 1982 Aug; 68(3):268-74. PubMed ID: 7085123
    [Abstract] [Full Text] [Related]

  • 14. IgG and IgE antibodies after immunotherapy with bee and wasp venom.
    Kemeny DM, Lessof MH, Patel S, Youlten LJ, Williams A, Lambourn E.
    Int Arch Allergy Appl Immunol; 1989 Aug; 88(1-2):247-9. PubMed ID: 2707888
    [Abstract] [Full Text] [Related]

  • 15. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by competitive inhibition in ELISA.
    Rieben R, Blaser K.
    J Immunol Methods; 1989 Apr 21; 119(1):1-8. PubMed ID: 2708823
    [Abstract] [Full Text] [Related]

  • 16. Changes in IgG and IgE antibody levels to bee venom during immunotherapy.
    Ferrante A, Mocatta F, Goh DH.
    Int Arch Allergy Appl Immunol; 1986 Apr 21; 81(3):284-7. PubMed ID: 3770979
    [Abstract] [Full Text] [Related]

  • 17. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.
    Varga EM, Francis JN, Zach MS, Klunker S, Aberer W, Durham SR.
    Clin Exp Allergy; 2009 Sep 21; 39(9):1353-7. PubMed ID: 19538349
    [Abstract] [Full Text] [Related]

  • 18. Immunological studies on bee-keepers: specific IgG and subclass typing IgG against bee venom and bee venom components.
    Urbanek R, Forster J, Ziupa J, Karitzky D.
    Klin Wochenschr; 1980 Nov 17; 58(22):1257-60. PubMed ID: 7464005
    [Abstract] [Full Text] [Related]

  • 19. Bee sting allergy in beekeepers.
    Eich-Wanger C, Müller UR.
    Clin Exp Allergy; 1998 Oct 17; 28(10):1292-8. PubMed ID: 9824397
    [Abstract] [Full Text] [Related]

  • 20. The IgE and IgG subclass antibody response in patients allergic to yellow jacket venom undergoing different regimens of venom immunotherapy.
    Djurup R, Malling HJ, Søndergaard I, Weeke B.
    J Allergy Clin Immunol; 1985 Jul 17; 76(1):46-55. PubMed ID: 4008813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.